Physician profile
Robert J Settipane
NPI 1750456042
$10,379.16
in general payments reported to CMS, 2019-2025
35 companies · $2,625 in 2025
The $2,625 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $462 · 2021: $1,000 · 2022: $1,673 · 2023: $2,270 · 2024: $2,090 · 2025: $2,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,886 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,885.77 |
| Education | $100.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,282.40 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $2,119.80 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,467.22 | 2019-2025 | Dupixent |
| Genzyme Corporation | $559.30 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $494.32 | 2020-2025 | |
| Pfizer INC. | $341.15 | 2019-2025 | |
| Genentech USA, INC. | $318.99 | 2019-2025 | Xolair |
| Pharming Healthcare, INC. | $318.75 | 2022-2025 | Ruconest |
| Amgen INC. | $276.81 | 2021-2025 | Tezspire |
| Optinose US, INC. | $219.86 | 2021-2025 | |
| Abbvie INC. | $204.91 | 2021-2023 | Rinvoq |
| Kaleo, INC. | $202.93 | 2020-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $179.81 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.96 | 2022-2024 | Spiriva Respimat, Stiolto Respimat |
| Hikma Pharmaceuticals USA | $142.21 | 2023-2024 | Ryaltris |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $131.62 | 2022-2024 | |
| Covis Pharma Gmbh | $113.24 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $104.94 | 2021-2024 | Orladeyo |
| Leo Pharma INC. | $104.34 | 2022-2024 | Adbry |
| Ars Pharmaceuticals Operations, INC. | $75.46 | 2025 | Neffy |
| Csl Behring | $73.45 | 2023-2024 | Hizentra, Haegarda |
| Galderma Laboratories, L.P. | $60.62 | 2025 | Nemluvio |
| Verona Pharma, INC. | $59.07 | 2025 | Ohtuvayre |
| Aimmune Therapeutics, INC. | $56.52 | 2020-2022 | |
| Blueprint Medicines Corporation | $52.80 | 2023 | Ayvakit |
| Incyte Corporation | $44.85 | 2022-2024 | Opzelura |
| Genentech, INC. | $42.10 | 2019 | |
| Organon LLC | $29.44 | 2025 | Vtama |
| Paratek Pharmaceuticals, INC. | $26.93 | 2025 | Xhance |
| Merck Sharp & Dohme LLC | $24.08 | 2023 | |
| Alk-Abello, INC | $20.75 | 2022 | |
| Horizon Therapeutics Plc | $20.31 | 2021 | |
| Arcutis Biotherapeutics, INC. | $19.55 | 2025 | Zoryve |
| Biocryst Pharmaceuticals, INC. | $16.27 | 2020 | |
| Eyevance Pharmaceuticals LLC | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Settipane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.